the 2017 who eml ab chapter · the expert committee recommended the appointment of a standing eml...
TRANSCRIPT
![Page 1: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/1.jpg)
08/10/2018 | Title of the presentation 1
The 2017 WHO EML AB chapter
(6th June 2017)
WHO HQ, Geneva 3rd October 2018
Nicola Magrini
Secretary, WHO Expert Committee on the Selection and Use of Essential Medicines,
Essential Medicines Department, WHO
![Page 2: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/2.jpg)
The 2017 AB update and A-Wa-Re Index
![Page 3: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/3.jpg)
08/10/2018 | Title of the presentation 3
Contents of the presentation
• The 2017 WHO EML AB chapter (6th June 2017)
• 1st and 2nd choice AB for 25 syndromes
• The AWARE (ACCESS, WATCH and RESERVE) categories
• Next steps/iterations/work in progress (EML 2019)
![Page 4: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/4.jpg)
EML AB 2017: syndromes considered
![Page 5: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/5.jpg)
EML 2017 applications: example/template
![Page 6: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/6.jpg)
EML 2017: final template
![Page 7: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/7.jpg)
EML ACCESS Group
• First and second choice AB for the 23 relevant/frequent syndromes
considered make the ACCESS Group (29 AB)
![Page 8: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/8.jpg)
EML 2017 AB listing
ACCESS Group
each AB: by indication
![Page 9: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/9.jpg)
EML AB (not just) listing: ACCESS
![Page 10: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/10.jpg)
EML AB (not just) listing: ACCESS
![Page 11: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/11.jpg)
EML AB (not just) listing: ACCESS
![Page 12: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/12.jpg)
EML WATCH Group
![Page 13: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/13.jpg)
CIA List: Critically Important Antimicrobials
First developed in 2005, last revision 5th 2016
Intended to help preserve the effectiveness of
antimicrobials
Reference to help formulate and prioritize risk
assessment and risk management strategies for
containing resistance coming from the food chain
(non-human use)
http://www.who.int/foodborne_disease/resistance/cia/en/
![Page 14: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/14.jpg)
Antimicrobial agents are ranked as
Critically important
Highly important
Important
Highest priority agents
Fluoroquinolones
3rd and 4th generation cephalosporins
Macrolides
Glycopeptides
Polymyxin (colistin)
Recommends not to use in animals or plants classes not currently used in food
producing animals (such as carbapenems) & new classes developed for humans
Ranking of Antimicrobials
![Page 15: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/15.jpg)
EML AB (not just simple) listing: ACCESS & WATCH GROUP
![Page 16: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/16.jpg)
AB RESERVE Group: implications for policies
![Page 17: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/17.jpg)
08/10/2018 | Title of the presentation 17
EML AB and AWARE
• The 2017 WHO EML AB chapter (6th June 2017)
• 1st and 2nd choice AB for 25 syndromes
• The AWARE (ACCESS, WATCH and RESERVE) categories
• Next steps/iterations/work in progress (EML 2019)
![Page 18: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/18.jpg)
![Page 19: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/19.jpg)
![Page 20: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/20.jpg)
08/10/2018 | Title of the presentation 20
Mike Sharland,
personal
communication
Penta-id.org
EML A-WA-RE index uses in DU PPS in >20.000 patients
![Page 21: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/21.jpg)
EML 2017: UTI urinary tract infections
![Page 22: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/22.jpg)
![Page 23: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/23.jpg)
08/10/2018 | Title of the presentation 23
Lancet ID Jan 2018
![Page 24: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/24.jpg)
08/10/2018 | Title of the presentation 24
EML AB and AWARE
• The 2017 WHO EML AB chapter (6th June 2017)
• 1st and 2nd choice AB for 25 syndromes
• The AWARE (ACCESS, WATCH and RESERVE) categories
• Next steps/iterations/work in progress (EML 2019)
![Page 25: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/25.jpg)
The ABC of implementation
Implementation:
Dissemination
Adoption
Education
Change
![Page 26: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/26.jpg)
WHO EML AB: A-WA-RE implications
• AB progressive change of status (AB are different, the more you use, the more
you lose them)
• The great potential: OneHealth common goals in human health, agriculture and
food producing animals
• The difficult (long-term) part: implementing optimal uses
![Page 27: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/27.jpg)
Back to basics on implementation
![Page 28: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/28.jpg)
![Page 29: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/29.jpg)
Where am I?
You’re 30 metres above the ground
in a balloon
You must be a researcher
Yes. How did you know?
Because what you told me is absolutely
correct but completely useless
You must be a policy maker
Yes, how did you know?
Because you don’t know where you are, you don’t know where you’re going, and now you’re blaming
me
J Lomas, 2007
![Page 30: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/30.jpg)
We need to look to non-traditional stewards, such as community
health workers and members of the public, in settings where health-
care professionals are a scarce resource.
Goff and Mendelson, Lancet ID, 2017
08/10/2018 | Title of the presentation 30
Global implementation/stewardship
![Page 31: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/31.jpg)
Effect size: moderate though higher than average Quality Improvement studies
February 2017
![Page 32: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/32.jpg)
Public Awareness
Campaigns: - Key messages
- Privilege contents
based on evidence
3 Priority Pathogens List
- R&D
6
Research Priorities &
GARDP new AB
7
Essential Diagnostics 8
Drug Utilization
- Hospital pps
- Community use
- Across sectors
(animals and
agricolture)
9
Animals & Agriculture
One Health
- CIA List (EML bridges)
10
Stewardship &
Education & audit
WHO package based
on new EML and 21
syndromes guidances
4
Implementation: context dependent and
research oriented
Health System
programs: monitoring
5
EML AB listing (3+) 1
Syndromes guidances
Comprehensive
Review of optimal use
2
5 Paediatric
Syndromes and STI
indications
New EML website: - database., new
format
- New App?
EML AB
strategy
2017
![Page 33: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/33.jpg)
The Expert Committee recommended the appointment of a standing EML working group to:
• consider reviewing additional clinical syndromes
• adapt the current clinical synopsis to produce short structured documents;
• coordinate the development for the EML and EMLc of a guidance document on
optimal dose and duration of antibiotic;
• review the differential effect of antibiotic classes on the selection of resistance;
• Define key stewardship messages associated with the new categorization and
develop more detailed guidance to assist with the implementation of
recommendations
08/10/2018 | Title of the presentation 33
EML 2017-2019: a standing AB WG
![Page 34: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/34.jpg)
08/10/2018 | Title of the presentation 34
EML AB and AWARE
• The 2017 WHO EML AB chapter (6th June 2017)
• 1st and 2nd choice AB for 25 syndromes
• The AWARE (ACCESS, WATCH and RESERVE) categories
• Next steps/iterations/work in progress (EML 2019)
![Page 35: The 2017 WHO EML AB chapter · The Expert Committee recommended the appointment of a standing EML working group to: • consider reviewing additional clinical syndromes • adapt](https://reader033.vdocument.in/reader033/viewer/2022042218/5ec3666448d9637e094f0976/html5/thumbnails/35.jpg)
• New syndromes: typhoid fever, AB surgical prophylaxis, dental infections
• New AB and AWARE categories
• Differences between amoxi and amoxi-clav
• New iteration of AWARE and AWARE targets (at least 60% Access … and an
Amoxi target for paed)
• An AB handbook and short guidances
• An AB/AMR electronic platform
08/10/2018 | Title of the presentation 35
EML 2019: AB work in progress